Zoetis Inc. $ZTS Shares Sold by Advisors Asset Management Inc.

Key Points

• Advisors Asset Management Inc. reduced its stake in Zoetis Inc. by 18.2% during the 1st quarter, selling 3,601 shares, and now holds a total of 16,132 shares worth approximately $2.66 million.
• Multiple institutional investors have shown increased activity, with Portside Wealth Group LLC raising its holdings by 24.7% and Tandem Investment Advisors Inc. increasing its stake by over 100% in the same period.
• Zoetis reported a quarterly earnings per share of $1.76, exceeding analysts' expectations, and projects an EPS of 6.30-6.40 for FY 2025.

Advisors Asset Management Inc. lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,132 shares of the company's stock after selling 3,601 shares during the quarter. Advisors Asset Management Inc.'s holdings in Zoetis were worth $2,656,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in Zoetis in the first quarter valued at approximately $616,375,000. Sarasin & Partners LLP acquired a new stake in Zoetis during the 1st quarter valued at $339,111,000. Mackenzie Financial Corp increased its stake in Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after buying an additional 1,782,110 shares during the period. GAMMA Investing LLC lifted its holdings in Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after buying an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC boosted its position in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of Zoetis stock traded down $2.28 during trading hours on Friday, reaching $148.33. The company's stock had a trading volume of 3,111,229 shares, compared to its average volume of 2,278,915. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company's 50 day simple moving average is $152.32 and its 200 day simple moving average is $157.31. The stock has a market cap of $65.74 billion, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Argus reaffirmed a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday. Finally, Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.